Targeted Pulse Quiz: September 8

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.

In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, discusses the background, findings, and implications of the phase 3 EMERALD trial.

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

The FDA has approved the WATER IV PCa trial, which will compare the safety and efficacy of Aquablation therapy to radical prostatectomy in patients with localized prostate cancer.

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.